

INVESTIGATIONAL NEW DRUG (IND) COMMITTEE
2017 Open Meeting
Friday, April 28th 2017, 9:00am – 12:00pm EDT
Mountbatten Salon, Chelsea Hotel, Toronto

AGENDA

Chairs: Dr. Scott Laurie and Dr. Philippe Bedard
 IND Program Director: Dr. Lesley Seymour

Start time	End time	Topic	Presenter
9:00	9:05	Welcome and introductions	Scott Laurie
9:05	9:10	Acknowledge and thank outgoing past and current IND Chair Handover to new current chair and announcement of new incoming IND	Lesley Seymour
9:10	9:15	IND Program Team Awards	Philippe Bedard
9:15	9:35	Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award & Lecture: Bench and bedside: translating academic discoveries with CCTG	Elizabeth Eisenhauer to David Cescon
9:35	9:55	Immune Checkpoint Inhibitors: Recognition and Management of Toxicity	Rosalyn Juergens
9:55	10:15	Early Phase Directions for Gynecologic Cancers	Stephanie Lheureux
10:15	10:35	iRECIST	Lesley Seymour
10:35	11:20	Discussion of trials: IND.213 IND.219 IND.221 IND.229	Vanessa Bernstein & Susan Ellard Penelope Bradbury & Barbara Melosky Hal Hirte Stephen Chia
11:20	11:40	Umbrella Trial for Prostate Cancer	Kim Chi
11:40	11:50	PM1 / Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II basket trial	Daniel Renouf
11:50	11:58	Update on IND Program: trials closed, current and planned	Lesley Seymour
11:58	12:00	Closing remarks	Lesley Seymour

Meeting Objectives

- To summarize aspects of recent developments in the understanding of immunotherapy, novel therapeutic agents as these relate to specific malignancies and their therapeutic targets.
- To describe and discuss results of recent Investigational New Drug studies conducted by the CCTG.
- To understand aspects new clinical trial methodologies in the field of early cancer drug development.